Clinical Trials Logo

Genital Wart clinical trials

View clinical trials related to Genital Wart.

Filter by:

NCT ID: NCT06465914 Not yet recruiting - Anal Cancer Clinical Trials

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Start date: July 30, 2024
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male subjects aged 18-45 years. The primary hypothesis in the study is the 9-valent HPV recombinant vaccine reduces the incidence of vaccine HPV types-related genital warts compared with placebo in Chinese men.

NCT ID: NCT06454175 Not yet recruiting - HPV Infection Clinical Trials

A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

Start date: July 5, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of 15-valent HPV vaccine in 9-45year-old participants.

NCT ID: NCT05584332 Terminated - Cervical Cancer Clinical Trials

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: December 9, 2022
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45 Years .

NCT ID: NCT05580341 Active, not recruiting - Cervical Cancer Clinical Trials

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.

NCT ID: NCT05518201 Completed - Anal Cancer Clinical Trials

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Start date: September 23, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.

NCT ID: NCT05372016 Completed - Cervical Cancer Clinical Trials

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: September 19, 2020
Phase: Phase 3
Study type: Interventional

The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.

NCT ID: NCT05371353 Recruiting - Vaginal Cancer Clinical Trials

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Start date: May 14, 2022
Phase:
Study type: Observational

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

NCT ID: NCT05027776 Recruiting - Vaginal Cancer Clinical Trials

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

NCT ID: NCT04905030 Enrolling by invitation - Cervical Cancer Clinical Trials

Education, Immigration and HPV Vaccination: an Informational Randomized Trial

Start date: April 28, 2021
Phase: N/A
Study type: Interventional

Counteracting misinformation on childhood vaccines remains a priority for public health in industrialized countries. Previous research showed that misinformation-induced vaccine hesitancy particularly concerns very highly or very lowly educated parents, and, especially in Europe, specific groups of immigrants. Misinformation framing directly targets specific sub-population of parents by exploiting different cognitive biases, and specific concerns based on cultural norms: this project aims at testing the effectiveness of similar framing techniques applied to positive information on the HPV vaccine by conducting a Randomized Controlled Trial in Stockholm, Sweden. It randomizes emotionally and scientifically/statistically framed information addressing the specific concerns reported by previous literature.

NCT ID: NCT04895020 Recruiting - Cervical Cancer Clinical Trials

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Start date: May 28, 2021
Phase: Phase 3
Study type: Interventional

This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years